Vor Biopharma (VOR) Competitors $27.19 -0.57 (-2.05%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$27.06 -0.13 (-0.46%) As of 10/24/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VOR vs. CRMD, AVBP, RZLT, IOVA, DNA, URGN, PRME, AKBA, TYRA, and AVXLShould you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include CorMedix (CRMD), ArriVent BioPharma (AVBP), Rezolute (RZLT), Iovance Biotherapeutics (IOVA), Ginkgo Bioworks (DNA), Urogen Pharma (URGN), Prime Medicine (PRME), Akebia Therapeutics (AKBA), Tyra Biosciences (TYRA), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry. Vor Biopharma vs. Its Competitors CorMedix ArriVent BioPharma Rezolute Iovance Biotherapeutics Ginkgo Bioworks Urogen Pharma Prime Medicine Akebia Therapeutics Tyra Biosciences Anavex Life Sciences CorMedix (NASDAQ:CRMD) and Vor Biopharma (NASDAQ:VOR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership. Which has more risk and volatility, CRMD or VOR? CorMedix has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Is CRMD or VOR more profitable? CorMedix has a net margin of 42.11% compared to Vor Biopharma's net margin of 0.00%. CorMedix's return on equity of 42.73% beat Vor Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets CorMedix42.11% 42.73% 34.19% Vor Biopharma N/A N/A N/A Does the media prefer CRMD or VOR? In the previous week, CorMedix had 9 more articles in the media than Vor Biopharma. MarketBeat recorded 24 mentions for CorMedix and 15 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.70 beat CorMedix's score of 0.68 indicating that Vor Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 3 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vor Biopharma 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in CRMD or VOR? 34.2% of CorMedix shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 5.3% of CorMedix shares are owned by company insiders. Comparatively, 0.5% of Vor Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation and earnings, CRMD or VOR? Vor Biopharma has lower revenue, but higher earnings than CorMedix. Vor Biopharma is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$43.47M20.06-$17.93M$0.7514.89Vor BiopharmaN/AN/AN/A-$273.20-0.10 Do analysts prefer CRMD or VOR? CorMedix currently has a consensus target price of $18.83, indicating a potential upside of 68.61%. Vor Biopharma has a consensus target price of $77.83, indicating a potential upside of 186.26%. Given Vor Biopharma's higher probable upside, analysts clearly believe Vor Biopharma is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00Vor Biopharma 2 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.45 SummaryCorMedix beats Vor Biopharma on 11 of the 15 factors compared between the two stocks. Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VOR vs. The Competition Export to ExcelMetricVor BiopharmaBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$186.36M$262.99M$2.55B$10.81BDividend YieldN/AN/A2.50%4.81%P/E Ratio-0.10N/A22.3430.95Price / SalesN/A341.04113.06133.69Price / CashN/AN/A43.1261.86Price / BookN/A2.8433.126.61Net IncomeN/A-$111.70M$6.87M$277.10M7 Day Performance-6.24%-0.63%1.14%2.57%1 Month Performance-19.13%-7.54%1.31%3.20%1 Year PerformanceN/AN/A84.68%33.22% Vor Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VORVor Biopharma2.5697 of 5 stars$27.19-2.1%$77.83+186.3%N/A$186.36MN/A-0.10140Analyst ForecastInsider TradeGap UpCRMDCorMedix3.6514 of 5 stars$10.18+1.0%$18.00+76.8%-14.3%$794.64M$43.47M13.5730Upcoming EarningsAnalyst ForecastGap UpAVBPArriVent BioPharma1.5654 of 5 stars$19.51-0.6%$39.14+100.6%-41.3%$791.50MN/A0.0040News CoverageAnalyst ForecastRZLTRezolute2.6007 of 5 stars$8.69-2.0%$14.50+66.9%+59.0%$789.30MN/A0.0040News CoverageAnalyst ForecastIOVAIovance Biotherapeutics4.2441 of 5 stars$2.18-2.7%$11.90+445.9%-78.9%$788.84M$164.07M-1.77500News CoverageAnalyst ForecastDNAGinkgo Bioworks1.3447 of 5 stars$13.27-12.2%$9.00-32.2%+66.9%$784.40M$227.04M0.00640News CoverageAnalyst ForecastURGNUrogen Pharma3.9181 of 5 stars$16.95+0.1%$32.00+88.8%+56.8%$784.17M$90.40M0.00200News CoverageAnalyst ForecastPRMEPrime Medicine3.1911 of 5 stars$5.45-6.0%$8.92+63.6%+32.3%$780.53M$4.96M-2.66234Positive NewsGap UpAKBAAkebia Therapeutics3.4998 of 5 stars$2.93+0.3%$6.75+130.4%+90.6%$776.87M$160.18M-17.23430Analyst ForecastTYRATyra Biosciences2.4011 of 5 stars$14.50-2.3%$32.00+120.7%-35.1%$772.81MN/A0.0020Analyst ForecastAVXLAnavex Life Sciences3.5489 of 5 stars$8.98-0.3%$44.00+390.0%+64.3%$771.33MN/A-15.7540News CoverageAnalyst Downgrade Related Companies and Tools Related Companies CRMD Competitors AVBP Competitors RZLT Competitors IOVA Competitors DNA Competitors URGN Competitors PRME Competitors AKBA Competitors TYRA Competitors AVXL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VOR) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBitcoin is dead?Bitcoin’s historic run may be ending — and Weiss Ratings’ Juan Villaverde, who’s nailed every major crypto bul...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
